

# Automated chip-based extraction of HPV mRNA from cervical samples


T.Baier<sup>1</sup>, T.Hansen-Hagge<sup>1</sup>, R.Gransee<sup>1</sup>, A.Crombé<sup>1</sup>, S.Schmahl<sup>1</sup>, C.Paulus<sup>1</sup>, K.S. Drese<sup>1</sup>, P.Grønn<sup>2</sup>, L.Solli<sup>2</sup>, I.M. Falang<sup>2</sup>, A. Karlgard<sup>2</sup>, F.Karlsen<sup>2</sup>, C.Martin<sup>3</sup>, H.Keegan<sup>3</sup>, J.O'Leary<sup>3</sup>, L.Furberg<sup>4</sup>,  
<sup>1</sup>Institut für Mikrotechnik Mainz GmbH, Germany, <sup>2</sup>NorChip AS, Klokkearstua, Norway,  
<sup>3</sup>Coombe Women&Infants University Hospital, Dublin, Ireland, <sup>4</sup>SINTEF ICT, Oslo, Norway



Contact: info@imm-mainz.de  
 www.imm-mainz.de

- mRNA is a valuable bio-marker for detection of many common diseases.
- Presence of mRNA indicates biological activity of an agent and avoids false positive results if marker activity is required.
- mRNA detection allows early detection of cancer and other diseases.
- New biomarkers for various kinds of diseases emerge regularly.
- Cervical cancer is one of the most frequent types of cancer among women worldwide [1].
- Nearly all cases of this cancer are directly linked to previous infection with one or more types of human papilloma virus (HPV) [2].
- Early diagnosis of persistent HPV infections and subsequent treatment prevent onset of the disease.
- Against this background, a **chip-based automated platform** for the extraction of nucleic acids, including HPV mRNA from cervical smears as a model system, has been developed.
- The device accepts 3 ml of a suspension of fixated cervical smear cells in PreservCyt™.
- After insertion of sample and chip into the device the extraction procedure proceeds without further user interaction.

## Experimental Set-up




Operating device for the automated extraction of mRNA from cervical samples, containing two syringe pumps for fluid actuation, motors for valve operation, a heater and electronics for device control. The device is operated by a customised LabView program.

## Results: Successful Extraction and Validation

- The device has been successfully tested on various cell lines (HeLa, Ms751, CaSki) which express HPV mRNA.
- Device performance was validated by Nucleic Acid Sequence Based Amplification (NASBA) of the eluate, using the PreTect® HPV-Proofer kit (NorChip AS, Klokkearstua, Norway).
- A sensitivity study reveals amplifiable eluate down to 5 cells.
- First results show successful extraction for clinical cervical smear samples also.

Cell line / cell count	CaSki	MS751	HeLa
50.000	HPV16: positive	HPV45: positive	HPV18: positive
5.000	HPV16: positive	HPV45: positive	HPV18: positive
500	HPV16: positive	HPV45: positive	HPV18: positive
50	HPV16: positive	HPV45: positive	HPV18: positive
5	HPV16: positive	HPV45: negative	HPV18: positive

Results of sensitivity study of the sample preparation procedure. Samples of different cell lines containing from 5 to 50.000 cells were processed.



Sample NASBA amplification curve for HeLa cell lines showing fluorescence intensity vs. Time.

## Conclusions and Outlook

- The sample preparation device presented here was developed within the project MicroActive. It is planned to integrate this device with a second automated instrument for on-chip parallel NASBA amplification and detection of several mRNA targets exemplified by different HPV types [3,4].
- This combined system may thus serve as a point of care system for the detection of gene expression directly in a physician's office, avoiding the often delayed analysis by a specialized laboratory.
- However, the device is not limited to cervical samples and opens the way for a wide range of similar sample preparation applications.
- With small modifications this system can be adapted to other fields of operation where it is desirable to analyse complex biological samples "in the field" and on a short timescale.
- This includes for example
  - > Foodstuff analysis / animal feed control
  - > Personalised Medicine, Point-Of-Care
  - > Forensics

## References/Acknowledgements

- [1] World Health Organization, "Fact sheet No. 297: Cancer", (2006)
- [2] J. M. M. Walboomers, et al., "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.", J. Pathol., 189, 1219, (1999).
- [3] A.Gulliksen, et al., "Parallel nanoliter detection of cancer markers using polymer microchips", Lab Chip, 2005, 5, 416-420
- [4] L. Furberg, et al., "RNA amplification chip with parallel microchannels and droplet positioning using capillary valves", Microsyst.Technol (2008) 14:673681.



This work was funded by the European commission under contract no. IST-NMT-CT-2005-017319.